<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058396</url>
  </required_header>
  <id_info>
    <org_study_id>IDEC-152-20</org_study_id>
    <secondary_id>MSKCC-02096</secondary_id>
    <secondary_id>CDR0000288828</secondary_id>
    <nct_id>NCT00058396</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</brief_title>
  <official_title>Phase I Study Of IDEC-152 (Anti-CD23 Monoclonal Antibody) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine a recommended phase II dose of IDEC-152 monoclonal antibody in patients with&#xD;
           relapsed or recurrent chronic lymphocytic leukemia.&#xD;
&#xD;
        -  Determine the safety profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive IDEC-152 monoclonal antibody IV over at least 2 hours on days 1, 2, 8, 15,&#xD;
      and 22.&#xD;
&#xD;
      Cohorts of 3-10 patients receive escalating doses of IDEC-152 monoclonal antibody until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which at least 2 of 3, 2 of 6, or 3 of 10 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-50 patients will be accrued for this study within 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lumiliximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed chronic lymphocytic leukemia OR small lymphocytic lymphoma&#xD;
&#xD;
               -  Stage III-IV OR&#xD;
&#xD;
               -  Stage I-II, if determined to have disease progression evidenced by 1 of the&#xD;
                  following characteristics:&#xD;
&#xD;
                    -  Rapid doubling of peripheral lymphocyte count&#xD;
&#xD;
                    -  Progressive lymphadenopathy&#xD;
&#xD;
                    -  Progressive splenomegaly&#xD;
&#xD;
                    -  B symptoms&#xD;
&#xD;
                    -  Grade 2 or 3 fatigue&#xD;
&#xD;
          -  CD23+ disease&#xD;
&#xD;
          -  Progressive disease after at least 1 prior chemotherapy course&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable arrhythmia&#xD;
&#xD;
          -  No evidence of ischemia on EKG within the past 14 days&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 at least 60% of predicted&#xD;
&#xD;
          -  DLCO at least 55% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             treatment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No secondary malignancy requiring active treatment (except hormonal therapy)&#xD;
&#xD;
          -  No serious nonmalignant disease that would preclude study participation&#xD;
&#xD;
          -  No active uncontrolled bacterial, viral, or fungal infection&#xD;
&#xD;
          -  No clinically active autoimmune disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer radioimmunotherapy&#xD;
&#xD;
          -  No prior exposure to IDEC-152 or anti-CD23 antibodies&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent hormonal therapy allowed for second malignancy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery (except for diagnostic surgery)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer investigational therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Adam Weiss, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

